Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Arbutus Biopharma Corp ABUS

Arbutus Biopharma Corporation is a clinical-stage biopharmaceutical company. The Company is leveraging its virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can potentially be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV) infection. Its HBV product pipeline includes Imdusiran and AB-101. Imdusiran is its proprietary, conjugated GalNAc, subcutaneously delivered RNAi therapeutic product candidate. AB-101 is an oral PD-L1 inhibitor that has the potential to reawaken patients’ HBV-specific immune response by inhibiting PD-L1. Its pipeline includes two product candidates that target various steps in the HBV viral lifecycle and consists of various programs: RNAi therapeutic (imdusiran, AB-729) and Oral PD-L1 Inhibitor (AB-101). RNAi therapeutics utilize a natural pathway within cells to silence genes by eliminating the disease-causing proteins that they code for.


NDAQ:ABUS - Post by User

Bullboard Posts
Comment by HARLEYDAVIDSON21on Oct 21, 2014 2:15pm
195 Views
Post# 23047966

RE:A lot of traders, very few investors on here.

RE:A lot of traders, very few investors on here.
Chaos83 wrote: How many people on here are actually researching Tekmira's prospects and willing to invest for the duration that it may take for that to play out? It seems a lot of people here are so polarized by the day to day action. I also love a well timed trade where I make a good return in hours, but that's not always the case and often I hold out for major news events. Why do traders lose faith so quickly when nothing material has happened?


Define investor?  :)

To me an investor is someone who actually makes $$$ on any stock.

I've made enough $$$ on this one stock in the last year to buy 5 others in the pharma business,so when I buy back it will be mostly profit.  :)

I've done my homework on this stock and quite realize the potential,besides TKM-E ...........but it's the way management is handling the PR [possibly because of the DOD]that is making me mad and the market definitely isn't showing much faith either.

I've stated a number of times that this will be a volatile stock for at least a year ,but when you're expecting a good jump on HBV tests that see the stock $$ drop instead of rising.......then something is wrong.


There won't be any major news coming about tests for months so the only way this stock will go up is more speculation abot TKM-E and who knows where it will go.............but being long on this stock doesn't mean you don't have to be wary,also.  :p

I've been burnt enough to know that you can't fall in love witrh any stock,even though it looks great now.

Anyone who owned any BRX will tell you all about that....................like me.  :(











Bullboard Posts

USER FEEDBACK SURVEY ×

Be the voice that helps shape the content on site!

At Stockhouse, we’re committed to delivering content that matters to you. Your insights are key in shaping our strategy. Take a few minutes to share your feedback and help influence what you see on our site!

The Market Online in partnership with Stockhouse